Drug Development

European regulatory authorities approve Glaxo SmithKline's Rotarix rotavirus vaccine

Published in Drug Week, March 31st, 2006

Avant Immunotherapeutics (AVAN) announced that its partner, GlaxoSmithKline (GSK) Biologicals, has received approval from the European Commission for Rotarix rotavirus vaccine in the European Union (EU).

Rotarix will be the first vaccine available to children in Europe for the prevention of gastroenteritis caused by rotavirus. GSK intends to introduce this vaccine throughout Europe now that marketing authorization has been granted.

"We are delighted that our partner GSK has received approval of Rotarix in Europe," said Una S. Ryan, PhD, president and CEO of Avant Immunotherapeutics. "European approval marks a significant milestone for the global...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry